To help readers navigate this mushrooming opportunity, I've put together a list of the top corporate leaders in the field.
The beaten-down biotech sector had one of the best weeks in a year. Are these names still oversold?
And It comes after one of the best days of the year for the biotech sector.
The shares of the under-the-radar biotech have had a strong run in recent months, so traders might want to watch for a pullback to buy.
Incompetence, omissions and even outright lies have categorized this federal attempt to 'stem' the pandemic.
Let's look at the moves in the exchange-traded funds for the sector -- and check on the utilities and mega-caps.
After watching the moves in Trillium Therapeutics, a Real Money reader wants to play CRDF. Here's the what the charts say.
Investors come into this week with 'all eyes' on the Kansas City Fed's economic symposium come week's end.
Watch Medigen stock, as the Taiwanese president becomes one of the first citizens of the island nation to roll up her sleeve.
Supernus Pharmaceuticals and Exelixis Inc. have the cash to be able to take some chances in order to improve their business prospects.